Bli medlem
Bli medlem

Du är här




GHENT, Belgium, 18 November 2016
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced, in accordance with Article 14 of the Belgian Law of 2 May
2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from FMR LLC.

FMR LLC has notified Ablynx that the shareholding in Ablynx held through
financial instruments by FMR Co., Inc., a subsidiary of Fidelity
Management&Research Company, which itself is a subsidiary of FMR LLC (the
ultimate parent company), has exceeded the 3% threshold as of 10 November

According to the notification, FMR Co., Inc.'s holding of Ablynx shares and
voting rights through financial instruments has increased to 1,888,006
shares, corresponding to 3.10% of the current 60,921,732 outstanding Ablynx
shares (versus 1.92% in the previous notification on 3 October 2016).

FMR LLC (taking into account the holdings of its subsidiary undertakings)
currently holds a total of 5,543,898 Ablynx shares, representing 9.10% of the
current 60,921,732 outstanding Ablynx shares.

The notified details are presented below:

| Name % of shares and voting rights % of shares and voting rights held through financial instruments Total of both |
| Shares Voting rights Shares Voting rights Shares Voting rights |
| FMR LLC 3.57% 3.57% 3.10% 3.10% 6.67% 6.67% |
| |
|Fidelity Management&Research Company |
|FMR Co., Inc. |
| FMR LLC 1.48% 1.498 1.48% 1.48% |
| |
|FIAM Holdings Corp. |
|Fidelity Institutional Asset Management Trust Company |
| FMR LLC 0.94% 0.94% 0.94% 0.94% |
| |
|FIAM Holdings Corp. |
| TOTAL 6.00% 6.00% 3.10% 3.10% 9.10% 9.10% |
The holdings attributable to FMR LLC arise from holdings of various
undertakings for collective investment that are managed by FMR Co., Inc.,
Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of
which are entities that are subsidiaries of, and controlled by, FMR LLC.
These undertakings for collective investment have granted FMR LLC
discretionary power to vote on behalf of all their securities in accordance
with the FMR LLC board proxy voting policy. FMR LLC is not a controlled

Full versions of all transparency notifications are available on Ablynx
website, under the sectionInvestors.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than45 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, immuno-oncology,
oncology and respiratory disease. The Company has collaborations with
multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Genzyme, Merck&Co., Inc., Merck KGaA, Novartis, Novo Nordisk and
Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found

For more information, please contact


Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68

Marieke Vermeersch
Director IR&Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03

Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations

FTI Consulting:

Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000

pdf format of the press release

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.